Trial Profile
Mul-1867 Inhalation Therapy for Pulmonary Exacerbations Caused by Burkholderia Cepacia in COPD and Cystic Fibrosis patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs MUL 1867 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors TGV-Laboratories
- 02 Mar 2016 According to a TGV Laboratories media release, the company has filed an application with the Food and Drug Administration seeking Orphan Drug Status for Mul-1867 to be tested on cystic fibrosis patients with life-threatening antimicrobial-resistant pulmonary infections.
- 29 Oct 2015 New trial record